Drug Eluting Balloon for Prevention of Hemodialysis Access Restenosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2020-08-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the effectiveness of paclitaxel-coated balloon catheter to prevent restenosis after PTA (percutaneous transluminal angioplasty) of hemodialysis access (HA) in comparison with the uncoated PTA balloon catheter.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Randomized Trial Comparing DEB Versus Conventional PTA for the Treatment of Hemodialysis AVF or AVG Stenoses

NCT01544907

Stenosis of Arteriovenous Dialysis Fistula Arteriovenous Graft Stenosis

COMPLETED NA

Drug-Eluting Balloon Angioplasty for the Treatment of Hemodialysis Vascular Access Stenosis (DEBAVAS)

NCT02408822

Dysfunction of Hemodialysis Vascular Access (Fistula and Graft)

ACTIVE_NOT_RECRUITING NA

Drug Eluting Balloon (DEB) vs Plain Old Balloon Angioplasty (POBA) in the Treatment of Failing Dialysis Access

NCT05173857

Vascular Diseases Kidney Diseases

COMPLETED NA

DEB-after-Cutting Balloon-PTA in Dialysis Fistula Stenosis

NCT02578784

Renal Insufficiency

UNKNOWN NA

Drug Eluting Balloons PTA in Infra-popliteal Arteries in Patients With Critical Limb Ischemia

NCT02498080

Critical Limb Ischemia

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In Canada, there are over 20,000 patients with chronic end-stage renal disease (ESRD)on long-term hemodialysis and the number is increasing rapidly.The creation of hemodialysis access (HA) (also called "lifeline" for dialysis patients) has become the most common type of vascular surgery. These HA are frequently complicated by dysfunction after their creation mainly due to neointimal hyperplastic stenosis (\> 60% at one year). PTA is an established cornerstone method of treating stenotic lesions because of its minimally invasive percutaneous nature and widespread availability.Although PTA has a high initial success rate,narrowing will often recur in 2-3 months hence requiring further interventions. There are currently no durable therapies for the prevention or treatment of HA dysfunction restenosis after PTA.

Recently drug eluting balloon (DEB) with paclitaxel have repeatedly demonstrated their effectiveness to prevent restenosis due to intimal proliferation in the coronary and peripheral arterial systems. The investigators believe that the DEB with paclitaxel will significantly decrease the HA restenosis rate at the treated site and therefore will improve the management of HA failures.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arteriovenous Fistulae Arteriovenous Graft

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Paclitaxel Eluting Balloon

Paclitaxel Eluting Balloon Angioplasty

Group Type EXPERIMENTAL

Paclitaxel Eluting Balloon Angioplasty

Intervention Type DEVICE

Conventional uncoated balloon

Percutaneous Transluminal Angioplasty (PTA)

Group Type ACTIVE_COMPARATOR

Percutaneous Transluminal Angioplasty (PTA)

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Paclitaxel Eluting Balloon Angioplasty

Intervention Type DEVICE

Percutaneous Transluminal Angioplasty (PTA)

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Passeo-18 Lux Passeo-18

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical or hemodynamic evidence of HA dysfunction according to the clinician's judgment
* Patients with AVF (arteriovenous fistulae)or AVG (arteriovenous graft) located in the forearm or upper arm and is \> 3 months old
* Minimum age of 18 years and written informed consent
* Target lesion stenosis is \<3.0 cm in length and \>50% in luminal diameter reduction
* Maximum of two secondary lesions (stenoses) if the following criteria are satisfied: The secondary lesion is located in the graft or peripheral veins, the secondary lesion is \<3.0 cm in length and located \>1.0 cm away from the target lesion, the secondary lesion is \>50% luminal reduction compared to the reference vessel diameter
* Reference vessel diameter between 4 to 7 mm
* The HA must not be thrombosed and the lesion can be crossed with guide wire before angioplasty
* Lesion site: from 2 cm above the arterial anastomosis to the superior vena cava
* Restenotic lesion (previously treated by PTA or stent) or de novo lesion

Exclusion Criteria

* Contraindication to angiography or PTA
* Intervention of the HA circuit within the past 30 days
* Systemic infection or a local infection associated with the graft
* The patient is pregnant
* Patient is enrolled in another investigational study.
* Life expectancy \< 12 months
* History of severe allergic reaction to contrast media or to paclitaxel

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No